Document is current
Any future updates will be listed below
-
Authors
Balta, Denise
Varghese, Anish
Prieto Huarcaya, Susy
Di Spiezio, Alessandro
Marques, André R. A.
Akdaş, Enes Yağız
Tabakacilar, Doğa
Drobny, Alice
Werner, Christian
Xiang, Wei
Mächtel, Rebecca
Dobert, Jan Philipp
Fejtova, Anna
Richter, Franziska
Küspert, Melanie
Arnold, Philipp
Saftig, Paul
Zunke, Friederike https://orcid.org/0000-0002-0408-6388
-
Funding
Funding for this research was provided by:
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 22 February 2024
Accepted: 7 August 2025
First Online: 29 August 2025
Declarations
:
: The use of both non-transgenic and transgenic mice in this study was conducted with ethical approval from the respective regulatory authorities. The experiments involving Ctsd KO mice and their non-transgenic littermates were approved by the Ministry of Energy, Agriculture, the Environment, and Rural Areas of Schleswig-Holstein under reference number V242–40536/2016 (81–6/16). Similarly, the use of Thy1 SNCA mice was approved by the Government of Lower Franconia, Bavaria, Germany, under reference number RUF-55.2.2-2532-2-1489.
: Not applicable.
: ARAM, PS and FZ are named as inventors on the patent: US 12,053,510 B2, #WO2019211320A1; ‘Treatment of neuronal ceroid lipofuscinosis’.
